Author + information
To investigate the effects of Bisdemethoxycurcumin (BDMC) on apoptosis of primary neonatal cardiomyocyte induced by staurosporine (STS).
The whole experiment was divided into control group, STS treatment group, BDMC pretreatment with STS treatment group and BDMC pretreatment group in the cultured neonatal mouse cardiomyocytes. Then, the cell viability, the cell apoptosis, the caspase-3 activity and the intracellular ROS level were measured by the CCK-8 assay kit, TUNEL assay kit, the caspase-3 activity assay kit and the reactive oxygen species assay kit respectively.
(1) Compared with STS group, 100μmol/L BDMC pretreatment potently increases the viability of cardiomyocytes(from 50% to 78%, P<0.01, n=10). (2) Compared with STS group, BDMC pretreatment can lower the caspase-3 activity (from 700 to 500, P<0.01, n=10) as well as the rate of apoptosis significantly (from 28% to 10%, P<0.01, n=5). (3) Compared with STS group, BDMC pretreatment can reduce the ROS level obviously (from 7.7 to 1.7, P<0.01, n=8).
Bisdemethoxycurcumin can inhibit apoptosis to exert cardiomyocyte protection through lowering the intracellular ROS level in staurosporine treatment.